5 min read
As of September 2025, the U.S. stock market is witnessing a mixed performance with the tech-heavy Nasdaq Composite reaching record highs, driven by strong performances from major tech companies like Tesla and Microsoft. Amidst this backdrop, investors are closely monitoring potential interest rate cuts by the Federal Reserve as inflation data presents a complex picture for economic growth. In such an environment, identifying high-growth tech stocks involves looking at companies that are not only innovating but also effectively navigating current economic challenges and leveraging emerging technologies to drive future growth.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
ACADIA Pharmaceuticals |
10.94% |
26.66% |
★★★★★☆ |
|
ADMA Biologics |
20.60% |
23.25% |
★★★★★☆ |
|
Palantir Technologies |
25.30% |
31.65% |
★★★★★★ |
|
Workday |
11.51% |
29.07% |
★★★★★☆ |
|
RenovoRx |
65.52% |
68.63% |
★★★★★☆ |
|
OS Therapies |
56.64% |
68.61% |
★★★★★☆ |
|
Circle Internet Group |
28.59% |
82.71% |
★★★★★☆ |
|
Vanda Pharmaceuticals |
22.66% |
59.11% |
★★★★★☆ |
|
Gorilla Technology Group |
27.68% |
129.58% |
★★★★★☆ |
|
Zscaler |
15.73% |
41.57% |
★★★★★☆ |
Click here to see the full list of 68 stocks from our US High Growth Tech and AI Stocks screener.
We’re going to check out a few of the best picks from our screener tool.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide therapeutics for hematology, blood disorders, and inflammatory and immunomodulatory diseases with a market cap of approximately $3.66 billion.
Operations: Protagonist Therapeutics focuses on developing peptide therapeutics, generating revenue primarily from its biotechnology segment, which reported $209.18 million.
Protagonist Therapeutics recently showcased its developments at multiple conferences, signaling robust engagement with the investment community and ongoing transparency in its operations. Despite a challenging fiscal quarter with a net loss widening to $34.77 million from $30.62 million year-over-year, the company’s strategic filings for diverse security offerings suggest preparation for scalable operations and potential future growth initiatives. Notably, Protagonist’s revenue is projected to grow at an impressive rate of 22% annually, outpacing the broader US market forecast of 9.6%. This growth is underpinned by significant expected annual earnings growth of 38.8%, highlighting potential recovery and profitability in the coming years despite current losses.
